Modifying the epigenome as a therapeutic strategy in myelodysplasia.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn , Issue , 2007, Pages 405-411

  Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DNA METHYLATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; GENOME; HUMAN; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPIGENESIS, GENETIC; GENOME; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 43749098795     PISSN: 15204391     EISSN: None     Source Type: Journal    
DOI: 10.1182/asheducation-2007.1.405     Document Type: Review

References (43)